Coldstream Capital Management Inc. Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Coldstream Capital Management Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 14.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 108,212 shares of the biopharmaceutical company’s stock after acquiring an additional 13,535 shares during the period. Coldstream Capital Management Inc.’s holdings in Pfizer were worth $3,114,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Gladius Capital Management LP lifted its position in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the last quarter. MFA Wealth Advisors LLC purchased a new stake in Pfizer in the second quarter valued at $29,000. Quarry LP purchased a new stake in Pfizer in the second quarter valued at $31,000. Financial Connections Group Inc. purchased a new stake in Pfizer in the second quarter valued at $34,000. Finally, Teachers Insurance & Annuity Association of America acquired a new position in Pfizer in the third quarter valued at $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on PFE. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Citigroup began coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.64.

Pfizer Stock Down 2.0 %

PFE stock opened at $25.58 on Wednesday. The company has a market cap of $144.96 billion, a P/E ratio of 34.57, a P/E/G ratio of 0.71 and a beta of 0.65. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company’s 50-day moving average price is $27.42 and its 200 day moving average price is $28.36. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. On average, research analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Friday, November 8th were issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.57%. The ex-dividend date was Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.